CGL5 | Factory Price | Cosmetic Peptides | 99% Purity | Fast Shipping
59 Inquiries
1415456-99-3
Pharmaceutical Grade
99%
HongKong
Tong Peptide
5mg/10vials
2026-09-11
retatrutide,TB-500,GHK-CU,peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].Basic Info
-
Product Name:
Cagrilintide
Other Name:Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin
CAS No.:1415456-99-3
Molecular Weight:0
EC Number:206-141-6
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
retatrutide,TB-500,GHK-CU,peptide
-
Location:
1-1, Kailuo Road, Taojia Town, Jiulongpo District, Chongqing
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
501-1000
-
Year of Establishment:
2023
-
-
Inquiry History59 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Cagrlintide
1 MT Jul 31, 2026 
United Kingdom
cagrilintrude
20 MG Jul 21, 2026
United States
Cagrilintide
1 KG Jul 17, 2026
United States
Cagrilintide
30 MG May 26, 2026
United Kingdom
CAGRILLINTED
10 May 3, 2026 
Hongkong, China
Cagrilintide
100 MG Apr 22, 2026
United Kingdom
Cagrilintide
1 KG Apr 14, 2026 
Ireland
Cagrilintide
10 PCS Apr 14, 2026
United States
Cargrilintide
10 MG Mar 19, 2026
United Kingdom
cagrilintide
10 MG Feb 18, 2026 
China
CagriSema cagrilintide 2.5mg+Samaglutide2.5mg
10 MG Jan 26, 2026 
South Korea
Cagrilintide
500 MG Jan 21, 2026 
Pakistan
cagrilintide
1 KG Dec 26, 2025
United States
Cagrilintide
20 MG Dec 19, 2025
United Kingdom
Cagrilintide
100 MG Dec 10, 2025 
Canada
All peptides
1001 MT Nov 12, 2025
United States
Cagrilintide
10 MG Oct 13, 2024
United States
Cagrilintide
1 MG Jun 3, 2024
United States
Retatrutid3
10 MT Aug 4, 2026
United States
Retatrutide
20 MT Jul 25, 2026 Post an enquiry for this product
